Q32 Bio Inc

QTTB

Company Profile

  • Business description

    Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

  • Contact

    830 Winter Street
    WalthamMA02451
    USA

    T: +1 718 999-0232

    https://www.q32bio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    29

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,979.4022.00-0.24%
CAC 407,813.9736.46-0.46%
DAX 4024,292.5551.730.21%
Dow JONES (US)44,766.33243.96-0.54%
FTSE 1009,144.9583.460.92%
HKSE25,667.18129.110.51%
NASDAQ21,059.3139.290.19%
Nikkei 22541,826.34655.021.59%
NZX 50 Index12,805.1311.070.09%
S&P 5006,367.969.050.14%
S&P/ASX 2008,709.4027.80-0.32%
SSE Composite Index3,605.7323.430.65%

Market Movers